What is the proper administration technique for 0.5 mg intramuscular haloperidol and which vital signs and adverse effects should be monitored?

Haloperidol 0.5 mg IM Administration and Monitoring Guideline for Nursing Staff

For acute agitation or delirium in adults, administer haloperidol 0.5 mg IM as a single deep intramuscular injection, and monitor vital signs (especially blood pressure and heart rate) every 15 minutes for the first hour, then hourly for 4 hours, while observing for extrapyramidal symptoms and sedation level.

Administration Technique

Preparation

• Verify the dose: 0.5 mg haloperidol (you'll need to draw up 0.1 mL from a 5 mg/mL ampule) 1
• Inspect the solution: Must be clear, colorless to pale yellow; discard if cloudy or contains particles 1
• Opening the ampule: Follow the color-coded breaking system—tap to move fluid down, position fingers on colored ring, apply firm pressure on colored point to snap open 1

Injection Site and Technique

• Site selection: Use the deltoid or ventrogluteal muscle (deep IM injection required) 1
• Needle size: Use a 21-23 gauge, 1-1.5 inch needle for adequate depth
• Technique: Inject slowly over 10-15 seconds to minimize local irritation 2
• Z-track method: Consider using to prevent medication leakage into subcutaneous tissue

Monitoring Parameters

Immediate Monitoring (First Hour)

Vital Signs - Every 15 minutes:

• Blood pressure: Watch for orthostatic hypotension (common side effect) 2
• Heart rate: Monitor for tachycardia or bradycardia
• Respiratory rate: Especially if patient received benzodiazepines concurrently 2
• Oxygen saturation: Maintain >92% in most patients

Clinical Assessment:

• Sedation level: Use a standardized scale (e.g., Richmond Agitation-Sedation Scale)
• Agitation control: Assess at 15 and 30 minutes—83% of patients show improvement within 30 minutes 3
• Mental status: Note orientation, coherence, and response to verbal stimuli

Extended Monitoring (Hours 1-4)

Vital Signs - Every hour:

• Continue blood pressure, heart rate, respiratory rate, oxygen saturation
• Peak effect occurs at 20-40 minutes IM 4

Critical Adverse Effects to Monitor

Extrapyramidal Symptoms (EPSEs) - Most Important Concern 2:

• Acute dystonia (muscle spasms, especially neck/jaw): Can occur within minutes to hours
  • Watch for: Torticollis, oculogyric crisis, tongue protrusion, difficulty swallowing
  • Action: Have diphenhydramine 25-50 mg IM/IV immediately available
• Akathisia (restlessness): Inner sense of restlessness, inability to sit still
• Parkinsonism: Tremor, rigidity, shuffling gait (usually later onset)

Cardiovascular Effects 1, 5:

• QT prolongation: Risk of torsades de pointes (rare but serious)
  • Higher risk with: Electrolyte imbalances, concurrent QT-prolonging drugs, cardiac disease
  • Baseline ECG recommended if patient has cardiac history or risk factors
• Hypotension: Especially with position changes—assist patient when ambulating

Sedation and Respiratory Depression 2:

• Excessive sedation: Difficulty arousing, slurred speech
• Respiratory depression: Rate <10/min, shallow breathing, oxygen desaturation
• Higher risk if combined with benzodiazepines—avoid concurrent use when possible 2

Neuroleptic Malignant Syndrome (NMS) - Rare but Life-Threatening 1:

• Signs: High fever (>38.5°C), severe muscle rigidity, altered mental status, autonomic instability
• Onset: Can occur hours to days after administration
• Action: Stop haloperidol immediately, call physician, prepare for ICU transfer

Dosing Considerations

Standard Adult Dosing 6:

• Initial dose: 0.5-1 mg IM
• Repeat dosing: Can give every 1-2 hours as needed (maximum 10 mg/24 hours for most adults)
• Your 0.5 mg dose is appropriate for initial management

Special Populations Requiring Lower Doses:

Elderly Patients 2, 6, 2, 7:

• Use 0.25-0.5 mg (your 0.5 mg dose is at the upper end)
• Maximum 5 mg/24 hours in elderly 6
• Higher risk of: Hypotension, falls, EPSEs, prolonged sedation
• Consider even lower starting dose (0.25 mg) in frail elderly 7

Patients with Hepatic/Renal Impairment 2:

• Start with lower doses (0.25-0.5 mg)
• Titrate more gradually

Patients with Parkinson's Disease or Lewy Body Dementia 2:

• Contraindicated—do not use haloperidol (high risk of severe EPSEs)
• Use alternative agents (quetiapine preferred)

Documentation Requirements

Document immediately after administration:

• Time of injection, dose, site used
• Baseline vital signs and mental status
• Indication (agitation, delirium, acute psychosis)
• Patient's response at 15,30, and 60 minutes
• Any adverse effects observed
• Need for repeat dosing or rescue medications

When to Call the Physician

Call immediately for:

• Systolic BP <90 mmHg or drop >30 mmHg from baseline
• Heart rate <50 or >120 bpm
• Respiratory rate <10/min or oxygen saturation <90%
• Any signs of dystonia or severe EPSEs
• Excessive sedation (difficult to arouse)
• Signs of NMS (fever, rigidity, confusion)
• No improvement in agitation after 60 minutes (may need alternative agent)

Call within 1 hour for:

• Mild EPSEs (tremor, restlessness)
• Persistent agitation requiring repeat dosing
• Orthostatic hypotension (symptomatic)

Common Pitfalls to Avoid

1. Don't combine with benzodiazepines initially—increases respiratory depression risk 2. If both needed, use sequentially with close monitoring.

2. Don't use IV route—haloperidol IM is NOT approved for IV use (higher QT prolongation risk) 1

3. Don't give repeat doses too quickly—allow 30-60 minutes to assess response before redosing 3, 4

4. Don't forget fall precautions—orthostatic hypotension is common; keep bed rails up, assist with ambulation 2

5. Don't use in patients with known prolonged QT—check medication list and history first 1

6. Don't assume agitation is psychiatric—rule out hypoxia, hypoglycemia, urinary retention, pain, constipation first 6

Alternative Agents (If Haloperidol Contraindicated or Ineffective)

• Olanzapine 10 mg IM: Similar efficacy, possibly faster onset, less EPSEs 4, 8
• Ziprasidone 20 mg IM: Effective alternative, requires ECG monitoring 4
• Midazolam 5 mg IM: Faster sedation but higher respiratory depression risk 4